We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
UK to design ‘digital pound’ that could fend off a future private tech rival
Ruling by US court will make companies think twice about using Chapter 11 schemes to handle lawsuits
Congress may eventually have to step in and create a new club to resolve mass torts
Ruling from US appeals court casts doubt on future of contentious ‘Texas two-step’ manoeuvre
A successful listing would focus J&J on its pharmaceutical and medical-device business
EV/ebitda multiple is rich, given the healthcare giant expects any potential cost savings to be ‘very modest’
Purchase of heart pumpmaker to help US pharma group focus on drugs and medical devices
Critics say the controversial legal manoeuvre allows companies to bypass their responsibilities. But judges are beginning to crack down
New Mexico and Mississippi say consumer company’s strategy is making a ‘mockery’ of bankruptcy law
Pharmaceutical group issues downbeat forecast despite better than expected quarterly results
This legal manoeuvre is setting a new precedent for corporations to evade accountability in America
US drugmaker seeks more tie-ups after existing collaboration yields new cancer treatment
Ruling opens a fresh chapter for resolving US tort cases
Fight moves to Congress after judge allows J&J to use scheme to help it settle billions in legal claims
Decision allows group to use the manoeuvre to manage tens of thousands of claims that its baby talc caused cancer
Lawyer who drafted statute says companies should not deploy it to ‘skirt’ their obligations
Asset managers call for pharma executive pay to be linked to equitable distribution of jabs
Two doses cut likelihood by up to 85%, according to real-world South African research
Country tackles one of the first waves of infections caused by Omicron variant
Drugmakers are stress-testing existing jabs while preparing new formulas
Plan to spin off consumer division has failed to thrill investors
Advisers benefit from multinationals’ current wave of spin-offs
A successful split of the consumer and pharma divisions would, on paper, unlock value
World’s largest healthcare group follows trend to slim down with plans to focus on pharmaceuticals
International Edition
